

RESEARCH REPORT

Marijuana withdrawal among adults seeking treatment for marijuana dependence

ALAN J. BUDNEY, PAMELA L. NOVY & JOHN R. HUGHES

University of Vermont, Burlington, Vermont, USA

Abstract

Aims. *The clinical relevance of marijuana withdrawal has not been established. This study is the first to document the incidence and severity of perceived marijuana withdrawal symptoms in a clinical sample of marijuana-dependent adults.* **Measurements.** *Fifty-four people seeking outpatient treatment for marijuana dependence completed a 22-item Marijuana Withdrawal Symptom checklist based on their most recent period of marijuana abstinence.* **Findings.** *The majority (57%) indicated that they had experienced \geq six symptoms of at least moderate severity and 47% experienced \geq four symptoms rated as severe. Withdrawal severity was greater in those with psychiatric symptomatology and more frequent marijuana use.* **Conclusions.** *This study provides further support for a cluster of withdrawal symptoms experienced following cessation of regular marijuana use. The affective and behavioral symptoms reported were consistent with those observed in previous laboratory and interview studies. Since withdrawal symptoms are frequently a target for clinical intervention with other substances of abuse, this may also be appropriate for marijuana.*

Introduction

Marijuana (cannabis) withdrawal is not recognized in the DSM-IV, as the manual states that there “have been some reports of withdrawal symptoms, but these have not yet been reliably shown to be clinically significant”.¹ The ICD-10 allows for a diagnosis of marijuana withdrawal, but it does not provide descriptors of the symptoms that comprise such a syndrome.² Given that non-human and human inpatient studies have demonstrated clearly that withdrawal can occur following abrupt cessation of marijuana or tetrahydrocannabinol (THC) administration (see below), the reason for its omission from DSM-IV appears due to the lack of generalizable,

controlled outpatient studies of the incidence and severity of marijuana withdrawal among regular users. Unfortunately, the exclusion of marijuana withdrawal from the DSM contributes to the perception that marijuana use has minimal risk for harm or development of dependence, and that the development of behavioral or pharmacological treatments specifically for marijuana dependence is not necessary. Indeed, these perceptions are inaccurate as marijuana use can produce dependence at rates comparable to other substances of abuse, increase psychiatric and medical problems and impair psychosocial functioning.^{3–6} Many marijuana users have difficulty quitting and maintaining abstinence

This paper was presented in part at the 1998 conference of the College on Problems of Drug Dependence, Scottsdale, AZ, USA.

Correspondence to: Alan J. Budney, Department of Psychiatry, University of Vermont, 200 Twin Oaks Terrace, S. Burlington, VT 05403, USA. e-mail: abudney@zoo.uvm.edu

Submitted 3rd August 1998; initial review completed 2nd November 1998; final version accepted 18th January 1999.

from marijuana; moreover, response to treatment and relapse rates among people seeking treatment for marijuana dependence are similar to those observed with other substances of abuse.^{7,8} Whether relapse in marijuana users is influenced by withdrawal symptoms has not been tested. If this were the case, then specific behavioral and pharmacological treatment for withdrawal could be useful in the treatment of marijuana dependence.

Early studies using rhesus monkeys showed clear evidence that withdrawal can occur following chronic administration of injected and oral THC.⁹⁻¹¹ Across these studies, abstinence effects observed included yawning, anorexia, piloerection, irritability, increase in gross motor movement, eye contact, tooth-baring, scratching, biting and licking fingers, hair-pulling, tremors, twitches, shaking, apparent hallucinations and disruption in operant responding. The discovery of the cannabinoid receptor (CB1) in the late 1980s and the subsequent development of a cannabinoid antagonist (SR 141716A) provided a more definitive means of testing for marijuana (THC) withdrawal. Antagonist challenge studies in which the cannabinoid antagonist is administered to animals following chronic dosing with THC have demonstrated a marked withdrawal syndrome in rats and dogs.¹²⁻¹⁴

Human inpatient laboratory studies confirmed the findings of the primate research. In these studies, subjects were typically confined to a research ward, provided free access to marijuana cigarettes for a specified number of weeks, and then access was discontinued.¹⁵⁻¹⁸ A fairly uniform set of signs and symptoms were observed following cessation of marijuana use including irritability, restlessness, sleep difficulties, decreased appetite and unco-operativeness. A more rigorous test of withdrawal occurred in a series of studies in which subjects were administered relatively high doses of oral THC (10-30 mg) every 3-4 hours, 24 hours a day.^{19,20} Cessation of THC dosing resulted in symptoms similar to those observed in the marijuana smoking studies. In addition, readministration of THC reduced subjective and objective withdrawal symptoms, and administration of a placebo resulted in no withdrawal symptoms when discontinued. These results were replicated in a recent, well-controlled laboratory study using smaller doses and a shorter duration of oral THC administration.²¹ It is important to

realize that inpatient studies where the subject's environment is restricted may substantially underestimate the severity of drug withdrawal because stimuli found in the user's usual environment can greatly increase withdrawal severity, e.g. conditioned withdrawal effects.²²⁻²⁴ Thus, withdrawal from regular, heavy marijuana smoking in the natural environment may be substantially greater than that observed in these inpatient studies.

Two interview studies of non-clinical samples of marijuana users support the findings of the laboratory research on marijuana withdrawal. In one study, structured interviews of 5611 individuals indicated that 16% of those with a lifetime history of frequent marijuana use described a history of marijuana withdrawal.²⁵ Typical symptoms included nervousness, restlessness, sleep difficulty and appetite change. Similarly, in the DSM-IV field trials 25% of people who had smoked marijuana at least six times in their life reported experiencing marijuana withdrawal, while 85% of those who were marijuana dependent reported withdrawal or tolerance.²⁶ Crowley and colleagues documented similar descriptions of marijuana withdrawal among adolescent substance abusers in residential care.²⁷ Seventy-eight per cent of these patients met DSM-criteria for marijuana dependence and 67% of these described a history of marijuana withdrawal, with the most common symptoms being irritability, restlessness, depressed mood, sleep difficulty and fatigue/yawning. Although all these interview studies are limited by the retrospective data collection, the results suggest that some level of marijuana withdrawal occurs among a subset of regular marijuana users when they stop smoking marijuana.

An abbreviated summary of the extant literature on marijuana withdrawal in humans is presented in Table 1. This literature suggests that a fairly consistent cluster of symptoms occurs under varying situations when chronic marijuana (THC) administration is discontinued abruptly. The purpose of the present study was to determine whether reports of marijuana withdrawal among adults seeking treatment for marijuana dependence are similar to those reported in the laboratory and interview studies of nonclinical samples of marijuana users. This information is needed to assess the importance of developing clinical strategies for assisting marijuana-dependent patients to cope with withdrawal

Table 1. *Marijuana (THC) abstinence symptoms reported across human laboratory and interview studies*

| | Human laboratory | | | | Interview | | Total ^a |
|-----------------|----------------------------------|---------------------------|--------------------------------------|----------------------------------|-------------------------------------|------------------------------------|--------------------|
| | Jones <i>et al.</i> , 1976 | Nowlan & Cohen 1977 | Georgatas <i>et al.</i> , 1979 | Haney <i>et al.</i> , 1999 | Weisbeck <i>et al.</i> , 1997 | Crowley <i>et al.</i> , 1998 | |
| Irritable | Y | Y | Y | Y | NA | Y | 5/5 |
| Nerv/tens | Y | NA | NA | Y | Y | Y | 4/4 |
| Restless | Y | Y | NA | Y | Y | Y | 4/4 |
| Sleep diff. | Y | Y | Y | Y | Y | Y | 5/5 |
| ↓↓↓Appetite | Y | Y | Y | Y | Y | Y | 5/5 |
| Anger (aggress) | Y | NA | Y | NA | NA | NA | 2/2 |
| Depression | N | NA | NA | NA | Y | Y | 2/3 |
| Craving | NA | Y | N | NA | NA | NA | 1/2 |

Y = Symptom reported in the study; N = symptom assessed, but did not occur; NA = Not able to determine if the symptom was assessed in the study. ^a Number of studies that found positive results/number of studies that had data available.

during quit attempts. In our outpatient marijuana abuse treatment clinic, 65% of marijuana-dependent patients reported a history of marijuana withdrawal,⁷ which is consistent with that reported in a previous study of treatment-seeking marijuana abusers.⁸ We developed a Marijuana Withdrawal Questionnaire to assess more carefully these reports of withdrawal. The present study reports findings from 54 patients who completed this questionnaire during an intake evaluation for entry into an outpatient marijuana treatment clinic. To our knowledge, this is the first report to document the incidence and severity of perceived marijuana withdrawal symptoms in a sample of adults who were seeking treatment for marijuana dependence.

Method

Participants

Participants were people seeking outpatient treatment for marijuana-related problems in a small metropolitan area (Burlington, VT, USA). All met DSM-III-R criteria for marijuana dependence as determined by the DSM Checklist.²⁸ Participants were recruited via newspaper advertisements, posters displayed in the community and public service announcements, all of which indicated that free treatment for marijuana-related problems was available. In addition, our recruitment sources included professional and other patient referrals. Individuals with severe psychiatric or medical problems (e.g. active psychosis, acute high risk for suicide, liver or renal failure) that would interfere with participation in

outpatient treatment were excluded. People who met DSM-III-R criteria for current alcohol or other drug dependence except nicotine were excluded. A total of eight people were excluded from this sample: two who did not meet marijuana dependence criteria, five who were alcohol-dependent and one who was cocaine-dependent. These selection criteria appear to reflect the typical person who seeks treatment specifically for marijuana-related problems.^{7,8}

The mean age of the participants was 33.8 ± 8.0 years. All were Caucasian, as the community in which this study was conducted includes only 1–2% ethnic minorities. Fifteen per cent of the sample were women. Eighty-two per cent were daily users of marijuana. The average number of times marijuana was smoked per day across the sample was 4.1 ± 3.4 . Fifty-four per cent of subjects were tobacco cigarette smokers who reported smoking a mean of 26.1 ± 16.5 cigarettes per day. Seventy-eight per cent were regular caffeine users. On average, subjects drank alcohol on 5.9 ± 9.1 days during the prior month. Forty-two per cent indicated they had problems with alcohol in the past. Thirty-two per cent reported past problems with cocaine. Forty-one per cent reported having a history of psychiatric problems, but structured interviews to determine specific psychiatric diagnoses were not conducted.

Intake assessment and measures

Written informed consent was obtained prior to the assessment. Intake workers under the super-

vision of a doctorate-level, clinical psychologist administered the following instruments: (a) DSM III-R checklist,²⁸ (b) Addiction Severity Index (ASI),²⁹ (c) drug-history questionnaire, (d) Time-Line-Follow-Back interviews (TLFB),³⁰ (e) Brief Symptom Inventory (BSI),³¹ (f) Beck Depression Inventory (BDI),³² (g) University of Rhode Island Change Assessment revised for marijuana use (URICA)³³ and (h) Situational Confidence Questionnaire revised for marijuana use (SCQ).³⁴ Intake workers were trained to administer the DSM-III-R checklist and the ASI via manual review, observation and supervised practice interviews. The psychologist reviewed all diagnoses and reinterviewed subjects if the diagnosis was not clear.

The DSM-III-R checklist is a semi-structured interview used to diagnose common Axis I psychiatric disorders and anti-social personality disorder.²⁸ Only the Psychoactive Substance Use Disorders section of the checklist was administered to make current substance-use diagnoses. The ASI is a clinical research interview used to assess problem severity in seven areas (medical, legal, alcohol, drug, employment, family and psychiatric).²⁹ ASI subscale composite scores were calculated for each problem area using the weighted combinations of individual items that provide reliable and valid measures of problem severity during the 30 days prior to the interview. A structured drug-history interview was used in combination with the TLFB³⁰ to collect information on frequency, quantity and patterns of substance use. TLFB is a reliable timeline method developed to assess problem drinker's reports of recent drinking, which we adapted to collect self-reported days and times per day of marijuana use. Information regarding the quantity of marijuana used (e.g. grams) was not obtained, as large within- and between-subject differences in the potency of marijuana used and the topography of marijuana smoking make quantity estimation of the active ingredient (delta-9-THC) highly variable and difficult to interpret.

The URICA provides an assessment of how ready an individual is to change a problem behavior;³³ we adapted this questionnaire for use with marijuana users. The URICA yields four subscale scores. A "readiness-to-change" score was computed by subtracting the precontemplation subscale score from the sum of the contemplation, action and maintenance subscales. The

Situational Confidence Questionnaire (SCQ) is a 39-item instrument that provides a measure of the individual's confidence in resisting use of alcohol across a variety of high-risk situations;³⁴ we adapted this questionnaire for use with marijuana users. The Brief Symptom Inventory (BSI) is a 53-item self-report inventory measuring psychiatric distress levels across nine subscales and three global indices of distress.³⁵ The Beck Depression Inventory is a 21-item questionnaire used to screen for severity of depressive symptomatology. Scoring of the self-report questionnaires was conducted according to the respective manuals or instructions provided by the authors.

Marijuana Withdrawal Checklist

The Marijuana Withdrawal Checklist lists 22 symptoms. Twelve of these items were taken from previously published human laboratory studies of marijuana withdrawal (i.e. craving, irritability, nervousness, depression, anger, restlessness, sleep problems, decreased appetite, increased appetite, strange dreams, headaches, violent outbursts). The other 10 items were associated with other substance withdrawal syndromes and were used as filler items so that we could examine the specificity of marijuana withdrawal. In addition, we included an open-ended "other" section to capture any additional symptoms subjects might report. Participants indicated which items were experienced during their most recent period of marijuana abstinence and rated each symptom's severity on a four-point scale (0 = not at all, 1 = mild, 2 = moderate, 3 = severe). Data were not available on how long ago the abstinence period occurred.

A total withdrawal discomfort score (WDS) was created by summing the severity ratings from the 10 symptoms reported by $\geq 40\%$ of the participants. The less frequently cited symptoms were excluded from this severity index as they were thought to have poorer specificity to marijuana withdrawal, and might obscure or confound relationships examined in exploratory analyses of factors related to withdrawal severity. The reliability of the 10-item WDS was $\alpha = 0.89$ supporting its use as a withdrawal severity scale. Of note, the Pearson correlation between the WDS and a total withdrawal score calculated using all 22 checklist items was 0.92.

Table 2. Percentage of patients who reported each withdrawal symptom and the severity rating (N = 54)

| | Mild rating ≥ 1 | Moderate rating ≥ 2 | Severe rating = 3 |
|-------------------|-------------------------|-----------------------------|----------------------|
| <i>Mood</i> | | | |
| Irritability | 87 | 64 | 40 |
| Nervousness | 80 | 53 | 33 |
| Depression | 76 | 59 | 28 |
| Anger | 74 | 56 | 24 |
| <i>Behavioral</i> | | | |
| Craving | 93 | 78 | 44 |
| Restlessness | 76 | 48 | 22 |
| Sleep problems | 67 | 43 | 19 |
| ↓↓↓Appetite | 50 | 30 | 11 |
| Strange dreams | 50 | 37 | 20 |
| ↑↑↑Appetite | 38 | 19 | 6 |
| Violent outbursts | 36 | 17 | 6 |
| <i>Physical</i> | | | |
| Headaches | 46 | 28 | 9 |
| Shakiness | 39 | 15 | 7 |
| Stuffy nose | 32 | 11 | 6 |
| Sweating | 20 | 13 | 4 |
| Hot flashes | 20 | 9 | 6 |
| Feverish | 20 | 13 | 6 |
| Diarrhea | 17 | 11 | 7 |
| Nausea | 19 | 13 | 6 |
| Muscle spasms | 15 | 8 | 6 |
| Chills | 17 | 11 | 6 |
| Hiccups | 6 | 2 | 2 |

Data analyses

This initial report provides descriptive statistics regarding the number and severity of withdrawal symptoms reported across participants. In addition, univariate, correlational and regression analyses were conducted to explore potential predictor variables of withdrawal severity.

Results

Symptom frequency and severity

The majority of participants reported experiencing multiple symptoms of marijuana withdrawal (Table 2). Eighty-five per cent reported four or more symptoms; on average, participants acknowledged 9.6 ± 5.1 symptoms. Most also reported symptoms of substantial severity. For example, 57% reported 6 or more symptoms of at least moderate severity (rating of ≥ 2) and 47% reported four or more symptoms rated as severe (rating = 3).

Specific symptoms of abstinence

The 10 symptoms reported by $\geq 40\%$ of the subjects were primarily affective and behavioral

in nature, i.e. craving, irritability, nervousness, restlessness, depressed mood, increased anger, sleep difficulties, strange dreams, decreased appetite and headaches (Table 2). These 10 symptoms were a subset of the 12 checklist items gleaned from the extant literature on marijuana withdrawal. None of the 10 items that were included in the checklist because of their association with other substance withdrawal syndromes were reported as marijuana withdrawal symptoms by greater than 40% of our subjects.

Correlational analyses

Intercorrelations among the 10 most frequently reported symptoms are presented in Table 3. Most symptoms were moderately correlated with each other. Affective symptoms (irritability, depressed mood, nervousness and anger) were most highly correlated. An insufficient sample size precluded conducting a factor analysis to determine whether checklist items formed discrete subscales or latent constructs.

The mean WDS was 14.4 ± 7.8 and ranged from 0 to 28. Correlations between WDS and

Table 3. Inter-correlations of withdrawal symptoms reported by greater than 40% of subjects

| | Craving | Irrit | Nervous | Restless | Depress | Anger | Sleep | Dreams | Appetite | Headache |
|------------------|---------|-------|---------|----------|---------|-------|-------|--------|----------|----------|
| Craving | — | 0.64 | 0.40 | 0.45 | 0.62 | 0.48 | 0.28 | 0.38 | 0.35 | 0.47 |
| Irritable | — | — | 0.61 | 0.38 | 0.67 | 0.51 | 0.21 | 0.19 | 0.33 | 0.41 |
| Nerv/tens | — | — | — | 0.59 | 0.78 | 0.72 | 0.48 | 0.39 | 0.42 | 0.39 |
| Restless | — | — | — | — | 0.59 | 0.44 | 0.69 | 0.47 | 0.44 | 0.45 |
| Depression | — | — | — | — | — | 0.69 | 0.47 | 0.36 | 0.45 | 0.49 |
| Anger | — | — | — | — | — | — | 0.34 | 0.34 | 0.28 | 0.30 |
| Sleep difficulty | — | — | — | — | — | — | — | 0.46 | 0.30 | 0.43 |
| Strange dreams | — | — | — | — | — | — | — | — | 0.35 | 0.39 |
| ↓↓Appetite | — | — | — | — | — | — | — | — | — | 0.34 |

Correlation coefficients > 0.26 are significant at $p < 0.05$. Correlation coefficients > 0.35 are significant at $p < 0.01$.

Table 4. Correlations between withdrawal discomfort score and baseline variables

| | Correlation coefficient |
|--------------------------------------|-------------------------|
| Age | - 0.09 |
| Gender (female) | 0.24 |
| Living with children (yes) | 0.24 |
| Years of marijuana use | 0.04 |
| Daily marijuana user (yes) | 0.06 |
| Times used per Day | 0.35** |
| Cigarette smoker (yes) | 0.20 |
| <i>Addiction Severity Index</i> | |
| Medical | 0.45** |
| Family/social | 0.37** |
| Legal | - 0.12 |
| Employment | - 0.16 |
| Psychiatric | 0.50** |
| Drug | 0.44** |
| Alcohol | - 0.17 |
| <i>Brief Symptom Inventory</i> | |
| Global symptom index | 0.51** |
| Somatization | 0.64** |
| Hostility | 0.59** |
| Anxiety | 0.49** |
| Obsess/comp | 0.43** |
| Interpersonal sens | 0.36** |
| Paranoid | 0.34* |
| Psychoticism | 0.33* |
| Depression | 0.32* |
| Phobic | 0.30* |
| Beck Depression Inventory | 0.57** |
| Readiness to Change | 0.40** |
| Situational confidence (total score) | - 0.33* |

** $p < 0.01$; * $p < 0.05$.

socio-demographic, psychosocial, psychiatric and substance-use variables collected at intake were typically moderate ($r = 0.3-0.6$) and occurred with many of the variables (Table 4).

Univariate analyses

Because the psychiatric variables were all significantly correlated with withdrawal severity, we performed additional analyses to compare withdrawal reports of those with high vs. low psychiatric severity. To do this, we split the sample into two groups using the clinical cut-off (T score of 63) on the Global Symptom Index of the BSI. Both groups reported multiple, mild to severe withdrawal symptoms (Table 5). However, the high psychiatric group ($N = 33$) reported a greater number and more severe symptoms than the low psychiatric group ($N = 19$), and the mean WDS was greater in the high group (16.8 ± 7.0 vs. 9.4 ± 7.0 , $p < 0.01$).

The relationship between past problems with substances other than marijuana abuse and marijuana withdrawal was explored to provide information on whether concurrent cessation of other abused substances may have influenced reports of marijuana withdrawal. An item from the drug history questionnaire (i.e. did you ever have a problem with any of the following substances) asked subjects to rate past problems with other substances on a four-point (0 = no problem, 1 = sometimes a problem, 2 = often a problem, 3 = always a problem). Subjects were dichotomized into two groups based on their response to this item. Those who reported any past problems of other substance abuse (a greater than 0 response for any substance) were included in the history-positive group (H+ : $N = 27$) and those who reported no history of problems were considered history-negative (H-: $N = 24$). Both groups reported substantial marijuana withdrawal. The mean WDS of the H+ group

Table 5. The number and severity of marijuana withdrawal symptoms reported by participants with high versus low psychiatric symptom severity

| Withdrawal symptom severity ^a | Number of withdrawal symptoms | | | | | |
|--|-------------------------------|-----------|------------|-----------|------------|-----------|
| | High psych | ≥ 4 | ≥ 6 | ≥ 8 | High psych | Low psych |
| | | Low psych | High psych | Low psych | | |
| Mild (≥ 1) | 91% | 74% | 88% | 53% | 82% | 42% |
| Moderate (≥ 2) | 79% | 42% | 67% | 37% | 51% | 16% |
| Severe (= 3) | 42% | 16% | 30% | 10% | 09% | 05% |

High psych (*N* = 33): this group included those with a *T*-score ≥ 63 on the Global Symptom Index of the BSI. Low psych (*N* = 19): this group included those with a *T*-score ≤ 62 on the Global Symptom Index of the BSI. ^a Item severity ratings from the Withdrawal Checklist range from 0 to 3 (none = 0, mild = 1, moderate = 2, severe = 3).

(16.1 ± 6.9) was greater than the H- group (12.7 ± 8.3), but this difference was not statistically significant (*p* = 0.12). A similar analysis comparing tobacco smokers versus non-smokers also revealed no significant between-groups difference on the WDS (*p* = 0.16).

Regression analyses

A stepwise regression using PROC STEPWISE (36) and a 0.15 significance level cut-off for entry into the model was performed to examine which variables were the best potential predictors of withdrawal severity. Only five independent variables were examined in this *post-hoc* analysis because of the sample size (*N* = 54). Each of the chosen variables was significantly correlated with withdrawal severity; each was not highly correlated with the other selected variables (*r* < 0.40); and each hypothetically represented a discrete association to withdrawal severity. The somatization score from the BSI was used because it was the psychiatric variable most highly correlated with withdrawal severity. The number of times marijuana was smoked per day was included as a measure of dose (i.e. frequency and quantity of use). The ASI Drug severity score reflected the overall severity of the patient's current drug abuse problems. The URICA readiness to change score was included as a measure of willingness to change marijuana use. The total score from the Situational Confidence Questionnaire was used to reflect confidence in abstaining from marijuana use. The regression yielded a final equation that included the somatization score (*p* < 0.01, partial *R*² = 0.43, the ASI drug score (*p* < 0.05, partial *R*² = 0.08), and times per day

marijuana was smoked (*p* < 0.05, partial *R*² = 0.05). The total *R*² achieved with this model was 0.56.

Discussion

The large majority of adults seeking outpatient treatment for marijuana dependence in this study reported a history of many withdrawal symptoms during previous periods of abstinence from marijuana (e.g. 85% reported ≥ four symptoms). Often these symptoms were rated severe (e.g. 47% reported ≥ four severe symptoms). These patients described behavioral and affective symptoms following cessation of marijuana use that were remarkably similar to those observed across prior laboratory and interview studies (see Table 1). The consistency of the specific symptoms reported within this study and across other studies suggests that a valid marijuana withdrawal syndrome occurs in a substantial number of marijuana abusers who abruptly stop using marijuana. Moreover, the number and magnitude of the perceived withdrawal symptoms described by our patients suggests that these abstinence effects may contribute to the development of marijuana dependence problems and may negatively influence attempts to stop marijuana use.

Before commenting on these findings, it merits note that they should be interpreted with caution due to the following methodological limitations. First, the symptom reports were collected retrospectively and were subject to memory bias (data were not available on how long ago withdrawal occurred). Prospective studies that assess symptom reports in marijuana-dependent

patients prior to, during, and following quit attempts are needed to obviate the potential for recall bias. Secondly, although we excluded marijuana-dependent subjects who were currently abusing other substances, many reported past problems with other substances (e.g. alcohol and cocaine). The historic reports of marijuana withdrawal collected in this study could have been confounded by simultaneous withdrawal from other substances (data were not available to address whether other drug use changed during the abstinence period). However, the fact that our *post-hoc* analyses failed to show a significant difference in marijuana withdrawal severity between subjects with versus without a history of other substance problems supports a conclusion that the reports of marijuana withdrawal provided in this study were not merely misattributions of withdrawal from other substances. Thirdly, our symptom questionnaire was labeled the "marijuana withdrawal checklist". Such labeling may have contributed to a positive response set resulting in an increased rate of false-positive symptom reports. Moreover, subjects were not provided with definitions to anchor their responses on the four-point severity scale. Related to this, we did not have baseline data with which to compare the abstinence symptom reports; that is, we do not know whether the withdrawal symptom reports differed significantly from symptoms experienced during periods of marijuana use.

With these limitations in mind, we comment on a few aspects of the findings. First, this study adds to the clinical data supporting the validity and potential clinical significance of a marijuana (cannabis) withdrawal syndrome. On average, our patients reported 6.4 symptoms of at least moderate severity. This number of symptoms exceeds the number (2–4) needed to meet criteria for any of the extant DSM-IV substance-withdrawal disorders.¹ In contrast to the conclusion of the DSM-IV substance-disorders committee (i.e. "the literature ... appears to make a compelling case for this rare but real disorder"³⁷), the present study suggests that marijuana withdrawal may commonly occur among patients seeking treatment for marijuana dependence.

A classic opioid- or alcohol-like withdrawal that includes discrete physiological and medical consequences is clearly not reported in most cases of marijuana withdrawal. However, the behavioral and affective withdrawal symptoms

reported in this study do overlap with those observed in other substance withdrawal syndromes.³⁸ Thus, if the clinical import of marijuana withdrawal is to be determined by comparing it to the physical/medical aspects of opioid or alcohol withdrawal, resistance to the acceptance of a significant marijuana withdrawal syndrome should be expected to continue. Historically, the use of such standards led to the opposition of and delay in the acceptance of alcohol, cocaine, nicotine and sedative withdrawal.³⁹ On the other hand, if the affective and behavioral symptoms reported by our marijuana patients are recognized as being important and similar to those observed during withdrawal from most other substances of abuse^{1,38}, then the clinical relevance of marijuana withdrawal should more readily become apparent.

Indeed, recent non-human research examining the effects of cannabinoid withdrawal on specific areas of the brain (i.e. limbic system) has provided additional evidence indicating that its effects are similar to other drug withdrawal syndromes.⁴⁰ For example, investigators have identified that a decrease in brain reward function occurs during withdrawal from most major drugs of abuse.⁴¹ The authors of these studies suggest that the behavioral consequences of the neurobiological changes observed during withdrawal are consistent with the type of symptoms (i.e. irritability, discomfort and negative affect) reported by our patients and patients withdrawing from other substances. Furthermore, they believe these common withdrawal symptoms may be as, if not more, important than drug-specific physiological consequences (e.g. piloerection, severe sweating or seizures) in determining whether the effects caused by the cessation of a substance contribute to the development of dependence and produce a clinically significant withdrawal syndrome.

The variable most highly correlated with withdrawal severity in the present study was psychiatric functioning. This finding emphasizes the need for baseline data to determine whether the described withdrawal symptoms merely reflect the usual symptom reports of people with significant psychiatric co-morbidity. A time-course analysis is also needed to examine the possibility that the abstinence effects we have described are not true withdrawal symptoms but are actually the simple off-set of drug effects seen in people who use marijuana to "self-medicate"

psychiatric symptoms. For example, if abstinence symptoms are increased compared to baseline and remain increased (i.e. do not return to baseline over time), this would indicate a return to a pre-marijuana use state, and thus simple drug off-set effects. An alternative interpretation supported by our *post-hoc* analysis which showed that participants without clinically significant psychiatric symptomatology also reported substantial withdrawal is that marijuana withdrawal occurs independent of psychiatric symptoms, yet its severity may be exacerbated by such pre-existing problems. This interpretation is bolstered by the fact that this pattern has been shown in several studies of nicotine withdrawal.^{42,43}

Our finding that the dose of the drug (times smoked per day) was related linearly to withdrawal severity further supports the contention that a valid withdrawal syndrome exists. Dose of drug predicts withdrawal severity across most substances.³⁸ Empirical support for this relationship has also been demonstrated with oral marijuana (THC) in human inpatient studies (20). Moreover, clinical case studies of very heavy marijuana users and reports from other cultures where very potent marijuana or hashish is common suggest that a relatively severe withdrawal syndrome can occur.⁴⁴⁻⁴⁸ Thus, the relationship of dose or potency to the severity of marijuana withdrawal may have important clinical relevance.

Much is yet to be learned regarding the clinical significance of marijuana withdrawal. Generalizable, controlled outpatient studies of post-cessation effects are needed to determine: (a) which effects are reliable and clinically relevant; (b) their severity and time—course; and (c) their role in cessation attempts and marijuana relapse. Moreover, studies with larger sample sizes will allow for the examination of the factor structure of Withdrawal Checklist items and facilitate a more comprehensive exploration of potential predictors of withdrawal severity. Indeed, if the mood and behavioral symptoms reported by our marijuana patients are found to be reliable and valid, then the inclusion of marijuana withdrawal in documents such as the DSM would assist in educating the greater scientific and lay communities regarding the abuse and harm potential associated with regular marijuana use. The delineation of a specific syndrome might also provide an important clinical

target for the development of behavioral and pharmacological treatments of marijuana dependence.

Acknowledgement

This research was supported by a grant from the National Institute on Drug Abuse, R29-DA08655.

References

1. AMERICAN PSYCHIATRIC ASSOCIATION (1994) *Diagnostic and Statistical Manual of Mental Disorders* (Washington, DC, Author).
2. WORLD HEALTH ORGANIZATION (1992) *ICD-10 Classification of Mental and Behavioural Disorders: clinical descriptions and diagnostic guidelines* (Geneva, Author).
3. KALANT, H., CORRIGALL, W. & SMART, R. (1997) *Cannabis Use: a health perspective and research agenda* (Geneva, Programme on Substance Abuse, WHO).
4. KANDEL, D. B. (1984) Marijuana users in young adulthood, *Archives of General Psychiatry*, 41, 200–209.
5. KANDEL, D., CHEN, K., WARNER, L. A., KESSLER, R. C. & GRANT, B. (1997) Prevalence and demographic correlates of symptoms of dependence on cigarettes, alcohol, marijuana and cocaine in the U.S. population, *Drug and Alcohol Dependence*, 44, 437–442.
6. KESSLER, R., MCGONAGLE, K., ZHAO, S. *et al.* (1994) Lifetime and 12-month prevalence of DSM III-R psychiatric disorders in the United States: results from the National Comorbidity Survey, *Archives of General Psychiatry*, 51, 8–19.
7. BUDNEY, A. J., RADONOVICH, K. J., HIGGINS, S. T. & WONG, C. J. (1998) Adults seeking treatment for marijuana dependence: a comparison to cocaine-dependent treatment seekers, *Experimental and Clinical Psychopharmacology*, 6, 419–426.
8. STEPHENS, R. S., ROFFMAN, R. A. & SIMPSON, E. E. (1993) Adult marijuana users seeking treatment, *Journal of Consulting & Clinical Psychology*, 61, 1100–1104.
9. BEARDSLEY, P. M., BALSTER, R. L. & HARRIS, L. S. (1986) Dependence on tetrahydrocannabinol in rhesus monkeys, *Journal of Pharmacology and Experimental Therapeutics*, 239, 311–319.
10. KAYMAKCALAN, S. (1973) Tolerance to and dependence on cannabis, *Bulletin on Narcotics*, 25, 39–47.
11. FREDERICKS, A. B. & BENOWITZ, N. (1980) An abstinence syndrome following chronic administration of delta-9-tetrahydrocannabinol in rhesus monkeys, *Psychopharmacology*, 71, 201–202.
12. ACETO, M., SCATES, S., LOWE, J. & MARTIN, B. (1996) Dependence on delta-9 tetrahydrocannabinol: studies on precipitated and abrupt withdrawal, *Journal of Pharmacology and Experimental Therapeutics*, 278, 1290–1295.

13. LICHTMAN, A. H., WILEY, J. L., LAVECCHIA, K. L. *et al.* (1998) Effects of SR 141716A after acute or chronic cannabinoid administration in dogs, *Journal of Pharmacology and Experimental Therapeutics*, 278, 1290–1295.
14. TSOU, K., PATRICK, S. L. & WALKER, J. M. (1995) Physical withdrawal in rats tolerant to delta-9-tetrahydrocannabinol precipitated by a cannabinoid receptor antagonist, *European Journal of Pharmacology*, 280, R13–R15.
15. GEORGOTAS, A. & ZEIDENBERG, P. (1979) Observations on the effects of four weeks of heavy marijuana smoking on group interaction and individual behavior, *Comprehensive Psychiatry*, 20, 427–432.
16. MENDELSON, J. H., MELLO, N. K., LEX, B. W. & BAVLI, S. (1984) Marijuana withdrawal syndrome in a woman, *American Journal of Psychiatry*, 141, 1289–1290.
17. MENDELSON, J. H., BABOR, T. F., KUEHENLE, J. C., ROSSI, A. M., BERNSTEIN, J. G. & MELLO, N. K. (1976) Behavioral and biologic aspects of marijuana use, *Annals of the New York Academy of Science*, 282, 186–210.
18. NOWLAN, R. & COHEN, S. (1977) Tolerance to marijuana: heart rate and subjective "high", *Clinical Pharmacology and Therapeutics*, 22, 550–556.
19. JONES, R. T. & BENOWITZ, N. (1976) The 30-day trip—clinical studies of cannabis tolerance and dependence, in: BRAUDE, M. C. & SZARA, S. (Eds) *Pharmacology of Marijuana*, pp. 627–642 (New York, Raven Press).
20. JONES, R. T., BENOWITZ, N. L. & HERNING, R. I. (1981) Clinical relevance of cannabis tolerance and dependence, *Journal of Clinical Pharmacology*, 21, 143S–152S.
21. HANEY, M., COMER, S. D., WARD, A. S., FOLTIN, R. W. & FISCHMAN, M. W. (1999) Abstinence effects following THC, *Psychopharmacology*, 41, 385–394.
22. SIEGEL, S. (1983) Classical conditioning, drug tolerance, and drug dependence, in: ISRAEL, Y., GLASER, F. B., KALANT, H., POPHAM, R. E., SCHMIDT, W. & SMART, R. G. (Eds) *Research Advances in Alcohol and Drug Problems*, pp. 207–246 (New York, Plenum Press).
23. WIKLER, A. (1980) *Opioid Dependence: mechanisms and treatment* (New York, Plenum Press).
24. STEWART, J., DEWIT, H. & EIKELBOM, R. (1984) The role of unconditioned and conditioned drug effects in the self-administration of opiates and stimulants, *Psychological Review*, 91, 251–268.
25. WEISBECK, G. A., SCHUCKIT, M. A., KALMIJN, J. A., TIPP, J. E., BUCHOLZ, K. K. & SMITH, T. L. (1996) An evaluation of the history of a marijuana withdrawal syndrome in a large population, *Addiction*, 91, 1469–1478.
26. COTTLE, L. B., SCHUCKIT, M. A., HELZER, J. E., CROWLEY, T., WOODY, G., NATHAN, P. & HUGHES, J. (1995) The DSM-IV field trial for substance use disorders: Major results, *Drug and Alcohol Dependence*, 38, 59–69.
27. CROWLEY, T. J., MACDONALD, M. J., WHITMORE, E. A. & MIKULICH, S. K. (1998) Cannabis dependence, withdrawal, and reinforcing effects among adolescents with conduct disorder symptoms and substance use disorders, *Drug and Alcohol Dependence*, 50, 27–37.
28. HUDZIAK, J., HELZER, J. E., WETZEL, M. W. *et al.* (1993) The use of the DSM-III-R checklist for initial diagnostic assessments, *Comprehensive Psychiatry*, 34, 375–383.
29. MCLELLAN, A. T., LUBORSKY, L., CACCIOLA, J. *et al.* (1985) New data from the Addiction Severity Index, *Journal of Nervous and Mental Disease*, 173, 412–423.
30. SOBEL, L. C. & SOBEL, M. B. (1992) Timeline follow-back: a technique for assessing self-reported alcohol consumption., in: ALLEN, J. P. & LITTEN, R. Z. (Eds) *Measuring Alcohol Consumption: psychosocial and biochemical methods*, pp. 41–72 (Totawa, NJ, Human Press).
31. DEROGATIS, L. R. (1993) *Brief Symptom Inventory: administration, scoring and procedures manual* (Minneapolis, MN, National Computer Systems Inc).
32. BECK, A., WARD, C., MENDELSON, M., MOCK, J. & ERBAUGH, J. (1961) An inventory for measuring depression, *Archives of General Psychiatry*, 4, 561–571.
33. MCCONNAUGHY, E. A., PORCHASKA, J. O. & VELICER, W. F. (1983) Stages of change in psychotherapy: measurement and sample profiles, *Psychotherapy: Theory Research and Practice*, 20, 368–375.
34. ANNIS, H. M. & GRAHAM, J. M. (1988) *Situational Confidence Questionnaire (SCQ-39) User's Guide* (Toronto, Canada, Addiction Research Foundation).
35. DEROGATIS, L. R. (1983) *SCL-90-R: administration, scoring and procedures manual—II* (Towson, MD, Clinical Psychometric Research).
36. FREUND, R. J., LITTELL, R. C. & SPECTOR, P. C. (1986) *SAS System for Linear Models 1986 Edition* (Cary, NC, SAS Institute).
37. CROWLEY, T. J. (1994) The organization of intoxication and withdrawal disorders, *DSM-IV Sourcebook*, pp. 93–107 (American Psychiatric Association).
38. HUGHES, J. R., HIGGINS, S. T. & BICKEL, W. K. (1994) Nicotine withdrawal versus other drug withdrawal syndromes: similarities and dissimilarities, *Addiction*, 89, 1461–1470.
39. EDWARDS, G. (1990) Withdrawal symptoms and alcohol dependence: fruitful mysteries, *British Journal of Addiction*, 85, 447–461.
40. DEFONSECA, F. R., CARRERA, M. R. A., NAVARRO, M., KOOB, G. F. & WEISS, F. (1997) Activation of corticotropin-releasing factor in the limbic system during cannabinoid withdrawal, *Science*, 276, 2050–2054.
41. JORDAN, M. P., WATKINS, S. S., KOOB, G. F. & MARKOU, A. (1998) Dramatic decreases in brain reward function during nicotine withdrawal, *Nature*, 393, 76–79.
42. COVEY, L. S., GLASSMAN, A. H. & STETNER, F. (1990) Depression and depressive symptoms in smoking cessation, *Comprehensive Psychiatry*, 31, 350–354.

43. GLASSMAN, A. H. & COVEY, L. S. (1996) Smoking and affective disorder, *American Journal of Health Behavior*, 20, 279–285.
44. BENSUSAN, A. D. (1971) Marijuana withdrawal symptoms, *British Medical Journal*, 3, 112.
45. DUFFY, A. & MILIN, R. (1996) Case study: withdrawal syndrome in adolescent chronic cannabis users, *Journal of the American Academy of Child and Adolescent Psychiatry*, 35, 1618–1621.
46. FRASER, J. D. (1949) Withdrawal symptoms in cannabis-indica addicts, *Lancet*, 2, 747–748.
47. ROHR, J. M., SKOWLUND, S. W. & MARTIN, T. E. (1989) Withdrawal sequelae to cannabis use, *International Journal of the Addictions*, 24, 627–631.
48. SOUEIF, M. I. (1967) Hashish consumption in Egypt, with special reference to psychosocial aspects, *Bulletin on Narcotics*, 19, 1–12.